Integrating Cleavage, Deprotection, And TFF: How Asahi Kasei's THESYS® Platform Is Reshaping Oligonucleotide Manufacturing

Traditional oligonucleotide production often relies on fragmented workflows, requiring manual handling and frequent material transfers between separate systems for cleavage, deprotection, and tangential flow filtration (TFF). These transitions not only introduce risks of product loss and exposure in hazardous environments but also demand significant cleanroom space. By consolidating these disparate unit operations into a single automated platform, manufacturers can achieve a seamless transition from reaction to purification.

This integrated approach utilizes a unified fluid handling architecture and specialized automation to manage controlled chemical dosing, temperature regulation, and pressure-driven membrane separation within one system boundary. Eliminating intermediate hold steps reduces footprint and simplifies cleaning validation for GMP compliance. This discussion explores the engineering challenges of combining these mechanisms and the resulting gains in operational efficiency and process safety. Discover how thoughtful system design is reshaping the future of therapeutic manufacturing by listening to the full podcast.